Nektar Therapeutics (NKTR) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Raises Price Target on Nektar Therapeutics (NKTR) to $15
November 7, 2016 8:58 AM ESTJefferies reiterated a Buy on Nektar Therapeutics (NASDAQ: NKTR), and raised the price target to $15.00 (from $14.00), following the company's 3Q earnings report. Based on the recently completed equity offering and mgts updated guidance, Jefferies now estimates FY16 & FY17 revenues and EPS of $170M & ($1.17) and $284 & ($0.57) vs $188M &... More
